Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Non-Opioid Pain Treatment Market Size Forecast: How Big Could The Market Get By 2030?
The non-opioid pain treatment market has demonstrated substantial expansion in recent years. The market is forecast to increase from $55.31 billion in 2025 to $60.32 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.1%. This historical expansion can be attributed to factors such as the rising prevalence of chronic pain conditions, heightened awareness concerning opioid-related risks, the restricted availability of non-opioid alternatives, an uptick in orthopedic and musculoskeletal procedures, and enhancements in hospital and clinic infrastructure dedicated to pain management.
The non-opioid pain treatment market is anticipated to experience robust expansion in the coming years. Its size is projected to reach $84.36 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.7%. This projected growth is fueled by factors such as the creation of innovative non-opioid therapeutics, the increased application of digital health monitoring and telemedicine for pain, the wider embrace of combination therapies, escalating government initiatives for pain management, and rising investment in personalized pain care and alternative treatments. Key trends during this period encompass the growing acceptance of non-opioid pain management solutions, the elevated consumption of medical cannabis and omega-3 fatty acid supplements, an increase in topical and injectable pain relief offerings, the broadening of pain management provisions within hospitals and clinics, and the incorporation of non-pharmacological methods like acupuncture and TENS.
Get A Free Sample Report With In-Depth Market Insights:
Non-Opioid Pain Treatment Market Demand Drivers Opening New Revenue Streams
An anticipated increase in sports-related injuries is projected to accelerate the expansion of the non-opioid pain treatment market moving ahead. These injuries refer to physical harm sustained either during or subsequent to participation in sports or exercise activities. The growing occurrence of such injuries stems from enhanced involvement in strenuous sports and recreational pursuits, thereby elevating athletes’ susceptibility to physical trauma. Non-opioid pain treatment proves beneficial for sports-related injuries, delivering effective alleviation of pain and diminished inflammation free from the dangers linked to opioid consumption, thus facilitating quicker recovery, better functionality, and more secure prolonged management. As an illustration, figures from October 2024, provided by the Howden Group Holdings Ltd, a UK-based insurance intermediary company, showed that during the 2023-24 football season, Europe’s top five leagues documented 4,123 injuries, representing a 4% rise from the prior season. Consequently, the increasing frequency of sports-related injuries is propelling the expansion of the non-opioid pain treatment market.
Non-Opioid Pain Treatment Market Segmentation: How Does The Market Break Down By Category?
The non-opioid pain treatment market covered in this report is segmented –
1) By Product: Medical Cannabis, Menthol-Containing, Omega 3 Fatty Acid-Containing, Botulinum Toxins, Capsaicin-Derived, Other Products
2) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (Nsaids), Acetaminophen, Local Anesthetics, Antidepressants, Anticonvulsants, Corticosteroids, Other Drug Classes
3) By Route Of Administration: Oral, Topical, Injectable, Other Route Of Administrations
4) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies
5) By Application: Orthopedic And Musculoskeletal Pain, Postoperative Pain, Cancer Pain, Neuropathic Pain, Other Applications
Subsegments:
1) By Medical Cannabis: Cannabidiol Based Products, Tetrahydrocannabinol Based Products, Combined Cannabinoid Products
2) By Menthol Containing: Topical Creams, Gels, Sprays
3) By Omega 3 Fatty Acid Containing: Fish Oil Derived Supplements, Algae Derived Supplements, Krill Oil Derived Supplements
4) By Botulinum Toxins: Onabotulinumtoxin A, Abobotulinumtoxin A, Incobotulinumtoxin A
5) By Capsaicin Derived: Low Concentration Creams, High Concentration Patches, Nasal Sprays
6) By Other Products: Magnesium Based Products, Acupuncture Devices, Transcutaneous Electrical Nerve Stimulation Devices
Non-Opioid Pain Treatment Market Trends Powering Strategic Industry Growth
Key players within the non-opioid pain treatment market are emphasizing advancements in drug formulations, such as non-opioid oral treatments, to provide effective pain relief and lessen the dangers tied to opioid use and addiction. Non-opioid oral treatment denotes orally delivered pain relief medications devoid of opioids, functioning via alternative mechanisms, including reducing inflammation, modulating nerve signals, or acting on specific receptors, to manage pain without the addictive potential or respiratory depression frequently linked to opioids. For instance, in July 2025, the US-based biotechnology company, Vertex Pharmaceuticals Incorporated, launched JOURNAVX, a pioneering non-opioid therapy offering efficient relief for moderate-to-severe acute pain. This advanced non-opioid treatment harnesses targeted modulation of pain pathways, presents a favorable safety profile, and achieves a rapid onset of action, thereby facilitating robust pain control, minimizing dependency potential, and improving patient well-being. It further guarantees precise pain management, reduces addiction probabilities, and aids in quicker recovery and a superior quality of life for individuals experiencing acute pain.
Non-Opioid Pain Treatment Market Competitive Overview And Top Companies
Major companies operating in the non-opioid pain treatment market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc, Novartis AG, GSK plc, Amgen Inc., Teva Pharmaceutical Industries Limited, Vertex Pharmaceuticals Incorporated, SUN PHARMACEUTICAL INDUSTRIES LIMITED, Perrigo Company Public Limited Company, Dr. Reddy’s Laboratories, HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY, Pacira BioSciences Inc, Heron Therapeutics Inc, AFT Pharmaceuticals Limited, Vivozon Pharmaceutical Co. Ltd, Levicept Ltd, Algiax Pharmaceuticals GmbH, Latigo Biotherapeutics Inc, Hyloris Pharmaceuticals SA
View The Full Non-Opioid Pain Treatment Market Report:
Non-Opioid Pain Treatment Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the non-opioid pain treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-opioid pain treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
